Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Anlotinib Dihydrochloride

Catalog No: tcsc0040093

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1360460-82-7

Formula:
$C_{23}H_{24}Cl_2FN_3O_3$

Pathway:
Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:
VEGFR;PDGFR;c-Kit

Purity / Grade:
>98%

Solubility:
DMSO

Alternative Names:
AL3818 Dihydrochloride

Observed Molecular Weight:
480.36

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit **VEGFR2/3**, **FGFR1-4**, **PDGFRα/β**, **c-Kit**, and **Ret**.

IC50 & Target: VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, Ret[1]

In Vitro: Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret[1]. The EC cell lines show differential sensitivity to Anlotinib Dihydrochloride (AL3818); AN3CA cells appear the most sensitive with an IC_{50} value of 84 nM. The other cell lines are approximately 28- to 550-fold less sensitive to Anlotinib Dihydrochloride. HEC1B cells have an IC_{50} value of 46 μM, and MFE296 cells are sensitive to Anlotinib Dihydrochloride, with an IC_{50} value of 2.9 μM compare with 3.2, 28.9, 29, and 40 μM for Ishikawa, MFE280, KLE, and HEC1A, respectively[2].

In Vivo: Within the Anlotinib Dihydrochloride (AL3818)-treated (5 mg/kg) group (n=11), tumor size is found to be reduced 26-fold, with an average tumor volume of 164.8±70 mm^3, when compare with the control group. Following treatment with Anlotinib Dihydrochloride, only 5 of the 11 mice are found to have residual tumor burden at the end of the treatment period. Treatment with Anlotinib Dihydrochloride decreases neoangiogenesis by 48.5% and cell proliferation by 27% when compare with the control group[2].